ANI Pharmaceuticals (ANIP) Competitors $98.81 +1.10 (+1.13%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$98.83 +0.02 (+0.02%) As of 05:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ANIP vs. ADMA, ANVS, RVMD, GRFS, RYTM, LEGN, ABVX, RNA, CYTK, and AXSMShould you be buying ANI Pharmaceuticals stock or one of its competitors? The main competitors of ANI Pharmaceuticals include ADMA Biologics (ADMA), Annovis Bio (ANVS), Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Abivax (ABVX), Avidity Biosciences (RNA), Cytokinetics (CYTK), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. ANI Pharmaceuticals vs. Its Competitors ADMA Biologics Annovis Bio Revolution Medicines Grifols Rhythm Pharmaceuticals Legend Biotech Abivax Avidity Biosciences Cytokinetics Axsome Therapeutics ANI Pharmaceuticals (NASDAQ:ANIP) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Is ANIP or ADMA more profitable? ADMA Biologics has a net margin of 44.06% compared to ANI Pharmaceuticals' net margin of -1.37%. ADMA Biologics' return on equity of 41.01% beat ANI Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ANI Pharmaceuticals-1.37% 25.03% 8.00% ADMA Biologics 44.06%41.01%28.47% Do insiders & institutionals believe in ANIP or ADMA? 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 3.7% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend ANIP or ADMA? ANI Pharmaceuticals currently has a consensus target price of $88.25, suggesting a potential downside of 10.69%. ADMA Biologics has a consensus target price of $27.67, suggesting a potential upside of 80.83%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts plainly believe ADMA Biologics is more favorable than ANI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ANI Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.10ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Does the media favor ANIP or ADMA? In the previous week, ANI Pharmaceuticals had 6 more articles in the media than ADMA Biologics. MarketBeat recorded 11 mentions for ANI Pharmaceuticals and 5 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.12 beat ANI Pharmaceuticals' score of 1.06 indicating that ADMA Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings & valuation, ANIP or ADMA? ADMA Biologics has lower revenue, but higher earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioANI Pharmaceuticals$614.38M3.49-$18.52M-$0.77-128.32ADMA Biologics$426.45M8.56$197.67M$0.8617.79 Which has more risk and volatility, ANIP or ADMA? ANI Pharmaceuticals has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. SummaryADMA Biologics beats ANI Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get ANI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIP vs. The Competition Export to ExcelMetricANI PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.12B$3.15B$5.80B$10.16BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-128.3221.2475.0826.39Price / Sales3.49420.70508.41175.01Price / Cash12.8644.4425.8129.91Price / Book5.179.6413.596.28Net Income-$18.52M-$53.20M$3.29B$270.38M7 Day Performance0.36%0.07%0.07%1.89%1 Month Performance12.96%4.27%4.57%6.01%1 Year Performance75.82%9.62%76.79%25.26% ANI Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIPANI Pharmaceuticals3.935 of 5 stars$98.81+1.1%$88.25-10.7%+68.9%$2.12B$614.38M-128.32600ADMAADMA Biologics3.6934 of 5 stars$16.42-2.7%$27.67+68.5%-15.4%$4.03B$426.45M19.09530Positive NewsANVSAnnovis Bio2.1317 of 5 stars$2.34+2.1%$17.33+641.4%-69.9%$44.62MN/A-1.153RVMDRevolution Medicines4.191 of 5 stars$41.06+1.4%$72.00+75.4%+5.7%$7.57B$11.58M-9.12250Insider TradeAnalyst RevisionGRFSGrifols3.9889 of 5 stars$10.11-0.2%$10.30+1.9%+4.0%$6.96B$7.81B8.6423,822RYTMRhythm Pharmaceuticals3.2887 of 5 stars$99.77-2.3%$101.57+1.8%+93.5%$6.78B$130.13M-33.15140Positive NewsLEGNLegend Biotech3.2015 of 5 stars$34.62-4.0%$74.22+114.4%-32.7%$6.66B$627.24M-39.342,609Positive NewsABVXAbivax2.3952 of 5 stars$90.00+2.2%$92.33+2.6%+632.7%$6.65BN/A0.0061Analyst UpgradeShort Interest ↑Gap DownRNAAvidity Biosciences2.1127 of 5 stars$48.05-4.6%$67.00+39.4%-3.6%$6.48B$10.90M-13.50190Analyst ForecastCYTKCytokinetics4.3881 of 5 stars$52.09-1.7%$75.38+44.7%-11.5%$6.34B$18.47M-10.21250Positive NewsInsider TradeAXSMAxsome Therapeutics4.9081 of 5 stars$129.29+3.3%$177.86+37.6%+24.7%$6.25B$385.69M-25.50380 Related Companies and Tools Related Companies ADMA Biologics Alternatives Annovis Bio Alternatives Revolution Medicines Alternatives Grifols Alternatives Rhythm Pharmaceuticals Alternatives Legend Biotech Alternatives Abivax Alternatives Avidity Biosciences Alternatives Cytokinetics Alternatives Axsome Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIP) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
